Aril® is the acellular amniotic tissue, featuring ease of patient application, long shelf life and reduced patient visits due to eye discomfort. These benefits make Aril® the amniotic tissue of choice for your practice:
What makes Aril® different?
Under the guidance of clinical and industry experienced experts, Aril is manufactured using a novel decellularization and stabilization process. Highly variable biologic materials are prepared through a dynamic purification process that depletes biomaterials of cell and cellular contents. This process does not impart unintentional alterations to the bioactive constituents of the extracellular matrix, such as long chain high molecular weight HA, collagens, fibronectin, proteoglycans, laminin, and growth factors. Bioactive constituents allow for a regulated and regenerative healing process.
Residual DNA Impacts Performance
Exacerbated or chronic inflammation and undesirable fibroblast activity are potential additional consequences of implanting product that contains non-self, low-molecular weight peptides.1,2,3,4 The presence of residual genetic DNA of donor cells in allograft tissues would be anticipated to have an additive effect on normal inflammation occurring as a part of the natural wound healing process. Additionally, it has been shown that the presence of residual DNA is correlated with increased fibroblast activity, which is recognized to be associated with fibrotic tissue formation.
Ease of Application
Aril® is very easy to apply, facilitating a uniform implementation across your practice. No up/down orientation means you’ll get it right the first time, without having to lift and reposition the tissue. And no need for an outer ring device that complicates the application process and is uncomfortable for the patient.
Available Sizes and Configurations
Aril®ﾠis an allograft tissue intended for homologous use and can be used in a variety of ophthalmology applications. It is regulated by 21 CFR Part 1271 and Section 361 of the PHS Act.
For specific instructions on the use and risks of Aril®ﾠproducts please refer to the instructions for use package insert.
References:ﾠ (1) Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials. 2009 Mar;30(8):1482-91.ﾠ (2) Keane TJ, Londono R, Turner NJ, Badylak SF. Consequences of ineffective decellularization of biologic scaffolds on the host response. Biomaterials. 2012 Feb;33(6):1771-81.ﾠ (3) Vandevord P, Singla A, Krishnamurthy B. The effects of DNA Extracts from Urological Tissue Matrices. Society for Biomaterials. 2006. (4)Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol. 1997 Jan;29(1):5-17.